Article
Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man.
Science translational medicine - 4 Jan 2012
Barnes Eleanor, Folgori Antonella, Capone Stefania, Swadling Leo, Aston Stephen, Kurioka Ayako, Meyer Joel, Huddart Rachel, Smith Kira, Townsend Rachel, Brown Anthony, Antrobus Richard, Ammendola Virginia, Naddeo Mariarosaria, O'Hara Geraldine, Willberg Chris, Harrison Abby, Grazioli Fabiana, Esposito Maria Luisa, Siani Loredana, Traboni Cinzia, Oo Ye, Adams David, Hill Adrian, Colloca Stefano, Nicosia Alfredo, Cortese Riccardo, Klenerman Paul
Abstract excerpt
Currently, no vaccine exists for hepatitis C virus (HCV), a major pathogen thought to infect 170 million people globally. Many studies suggest that host T cell responses are critical for spontaneous resolution of disease, and preclinical studies have indicated a requirement for T cells in protection against challenge. We aimed to elicit HCV-specific T cells with the potential for protection using a recombinant...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
